COLO.B.DK

644.2

+1.51%↑

GMAB.DK

1,322

+2.12%↑

AMBUB.DK

105.2

+3.44%↑

COLO.B.DK

644.2

+1.51%↑

GMAB.DK

1,322

+2.12%↑

AMBUB.DK

105.2

+3.44%↑

COLO.B.DK

644.2

+1.51%↑

GMAB.DK

1,322

+2.12%↑

AMBUB.DK

105.2

+3.44%↑

COLO.B.DK

644.2

+1.51%↑

GMAB.DK

1,322

+2.12%↑

AMBUB.DK

105.2

+3.44%↑

COLO.B.DK

644.2

+1.51%↑

GMAB.DK

1,322

+2.12%↑

AMBUB.DK

105.2

+3.44%↑

Search

Novo Nordisk A-S (Class B)

Затворен

425.75 -1.72

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

414.45

Максимум

449.95

Ключови измерители

By Trading Economics

Приходи

804M

29B

Продажби

-7.6B

78B

P/E

Средно за сектора

18.799

56.602

EPS

6.53

Дивидентна доходност

3.58

Марж на печалбата

37.182

Служители

76,302

EBITDA

4.1B

39B

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+9.53% upside

Дивиденти

By Dow Jones

Дивидентна доходност

Средно за сектора

3.58%

2.45%

Следващи печалби

6.08.2025 г.

Следваща дата на екс-дивидент

14.08.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-62B

2T

Предишно отваряне

427.47

Предишно затваряне

425.75

Novo Nordisk A-S (Class B) Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

16.05.2025 г., 11:36 ч. UTC

Топ новини

Novo Nordisk CEO to Step Down Amid Market Challenges

12.05.2025 г., 09:36 ч. UTC

Значими двигатели на пазара

Global Pharma Stocks Fall as Trump Plans to Cut Drug Prices

7.05.2025 г., 11:29 ч. UTC

Топ новини
Печалби
Значими двигатели на пазара

Novo Nordisk Investors Breathe Sigh of Relief Despite Guidance Hit From Copycat Drugs -- 2nd Update

7.05.2025 г., 07:05 ч. UTC

Печалби

Novo Nordisk Cuts Guidance as Copycat Versions of Ozempic Hit Sales -- Update

7.05.2025 г., 06:19 ч. UTC

Печалби

Novo Nordisk Cuts Guidance as Copycat Versions of Ozempic Hit Sales

16.05.2025 г., 18:35 ч. UTC

Топ новини

Ozempic Drugmaker's CEO Pushed Out Amid Weight-Loss Market Challenges -- 3rd Update

16.05.2025 г., 17:34 ч. UTC

Топ новини

Ozempic Drugmaker's CEO Pushed Out Amid Weight-Loss Market Challenges -- 2nd Update

16.05.2025 г., 13:42 ч. UTC

Горещи акции

Stocks to Watch Friday: Charter, Novo Nordisk, Applied Materials -- WSJ

16.05.2025 г., 13:27 ч. UTC

Пазарно говорене

Novo Nordisk CEO Departure Comes as a Surprise -- Market Talk

16.05.2025 г., 13:15 ч. UTC

Топ новини

Ozempic Drugmaker's CEO Pushed Out Amid Weight-Loss Market Challenges -- Update

16.05.2025 г., 12:17 ч. UTC

Печалби

Novo Nordisk Chairman: No Link Between CEO Change and Other Recent Exec Departures

12.05.2025 г., 22:14 ч. UTC

Топ новини

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- 2nd Update

12.05.2025 г., 18:45 ч. UTC

Топ новини

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- Update

12.05.2025 г., 12:07 ч. UTC

Пазарно говорене

Trump's Drug Price Cap Plan Is 'Alarming' for Pharma Sector -- Market Talk

12.05.2025 г., 07:20 ч. UTC

Пазарно говорене

Pharma Shares Face Risks From Trump's Pricing Plans -- Market Talk

7.05.2025 г., 15:13 ч. UTC

Печалби

These Stocks Are Moving the Most Today: Super Micro, AMD, Marvell, Disney, Uber, Arista, Sarepta, Charles River, and More -- Barrons.com

7.05.2025 г., 13:56 ч. UTC

Печалби

Novo Nordisk Stock Jumps After Earnings. Compounding Market's Growth Took it By Surprise -- Barrons.com

7.05.2025 г., 13:45 ч. UTC

Печалби

These Stocks Are Moving the Most Today: Super Micro, AMD, Marvell, Disney, Uber, Nordisk, Sarepta, EA, Upstart, and More -- Barrons.com

7.05.2025 г., 11:25 ч. UTC

Печалби

These Stocks Are Moving the Most Today: Super Micro, AMD, Disney, Uber, Novo Nordisk, Sarepta, EA, Tesla, and More -- Barrons.com

7.05.2025 г., 11:18 ч. UTC

Печалби

Novo Nordisk Stock Jumps After Earnings. It Cuts Guidance as Weight-Loss Drug Sales Slow. -- Barrons.com

7.05.2025 г., 09:55 ч. UTC

Печалби

These Stocks Are Moving the Most Today: Super Micro, AMD, Novo Nordisk, Sarepta, EA, Rivian, Disney, and More -- Barrons.com

7.05.2025 г., 09:36 ч. UTC

Печалби

These Stocks Are Moving the Most Today: Super Micro, AMD, Novo Nordisk, Sarepta, EA, Rivian, Tesla, and More -- Barrons.com

7.05.2025 г., 09:04 ч. UTC

Печалби
Горещи акции

Stocks to Watch Wednesday: Disney, Uber, Super Micro -- WSJ

7.05.2025 г., 08:10 ч. UTC

Пазарно говорене

Novo Nordisk Cuts Guidance Slightly More Than Expected -- Market Talk

7.05.2025 г., 08:08 ч. UTC

Пазарно говорене

Novo Nordisk's Downgraded Guidance Assumes Large Wegovy Uplift in 2H -- Market Talk

7.05.2025 г., 07:11 ч. UTC

Пазарно говорене
Печалби

Novo Nordisk Shares Seen Under Pressure After Downgrade -- Market Talk

7.05.2025 г., 05:39 ч. UTC

Печалби

Novo Nordisk: Sales Outlook Assumes Reduction in Patients on Compounded GLP-1 Treatments During 2H25

7.05.2025 г., 05:38 ч. UTC

Печалби

Novo Nordisk 1Q Wegovy Drug Sales Rose 83% To DKK17.36B, Consensus Saw DKK18.5B

7.05.2025 г., 05:37 ч. UTC

Печалби

Novo Nordisk 1Q Ozempic Drug Sales Rose 15% To DKK32.72B, Consensus Saw DKK32.01B

7.05.2025 г., 05:36 ч. UTC

Печалби

Novo Nordisk 1Q Gross Margin 83.5% Vs 84.8%

Сравнение с други в отрасъла

Ценова промяна

Novo Nordisk A-S (Class B) Прогноза

Ценова цел

By TipRanks

9.53% нагоре

12-месечна прогноза

Среден 1,162.73 DKK  9.53%

Висок 1,550 DKK

Нисък 720 DKK

Според 11 анализатори от Wall Street, предложили 12-месечна ценова цел за Novo Nordisk A-S (Class B) през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

11 ratings

7

Купи

2

Задържане

2

Продай

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Novo Nordisk A-S (Class B)

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.